CD274 and cancer: The efficacy of FMT as an anti- cancer therapy still under studies in conjugation with immune checkpoint blockade inhibitors like anti- PD1/PD-L1 or anti- CTLA4 antibodies (142–145) and are in different phases of clinical trials (NCT03353402, NCT03341143, NCT03772899, NCT03819296, NCT04577729, NCT04116775, NCT04758507, NCT04951583, 04988841, NCT05286294, NCT05279677, NCT0438619, NCT05008861, NCT04521075, NCT03819296, NCT05251389).